| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Greenwich Lifesciences, Inc. (GLSI) has 1 insider with recent SEC Form 4 filings, including 10 buys and 0 sells. GLSI is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 5.60M | $127.89M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 27, 2023 | Patel Snehal | CEO And CFO | Buy | 2,000 | $19.35 | $38,700.00 | - | |
| Jan 27, 2023 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 250 | $19.20 | $4,800.00 | - | |
| Jan 20, 2023 | Patel Snehal | CEO And CFO | Buy | 1,500 | $17.37 | $26,055.00 | - | |
| Jan 13, 2023 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 250 | $16.50 | $4,125.00 | - | |
| Jan 6, 2023 | Patel Snehal | CEO And CFO | Buy | 1,500 | $15.18 | $22,770.00 | - | |
| Dec 29, 2022 | Patel Snehal | CEO And CFO | Buy | 4,000 | $15.19 | $60,760.00 | +0.1% | |
| Dec 16, 2022 | Patel Snehal | CEO And CFO | Buy | 1,000 | $13.01 | $13,010.00 | - | |
| Dec 16, 2022 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 250 | $12.94 | $3,235.00 | - | |
| Dec 9, 2022 | Patel Snehal | CEO And CFO | Buy | 2,000 | $13.11 | $26,220.00 | - | |
| Dec 2, 2022 | Patel Snehal | CEO And CFO | Buy | 1,000 | $13.84 | $13,840.00 | - |